FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC

The FDA approved amivantamab therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MARIPOSA-2 trial, with data first shared at ESMO 2023 in Madrid with a simultaneous publication in the Annals of Oncology. Lung Cancer Considered host Dr. Stephen Liu talks with two leading oncologists to learn more about this research and how the therapy will be used by clinicians.